Continuation of anakinra despite the development of a pruritic rash in an otherwise refractory case of adult-onset Still's disease

Annals of the Rheumatic Diseases

Volumn 68, Issue 3, 2009, Pages 450-451

  Vordenbaumen S ^a   Ostendorf, B ^a   Sander, O ^a   Richter, J ^a   Schneider, M ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; C REACTIVE PROTEIN; CLEMASTINE; CYCLOPHOSPHAMIDE; ETANERCEPT; FERRITIN; GLUCOCORTICOID; LORATADINE; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ADULT ONSET STILL DISEASE; ARTHRALGIA; CASE REPORT; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FERRITIN BLOOD LEVEL; FEVER; HUMAN; LETTER; MALE; MYALGIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; RELAPSE; REMISSION; SKIN BIOPSY; SKIN PRURITUS; SPLENOMEGALY;

ANTIRHEUMATIC AGENTS; DRUG ERUPTIONS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; PRURITUS; REMISSION INDUCTION; STILL'S DISEASE, ADULT-ONSET;

EID: 61449170183     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.093492     Document Type: Letter

References (8)

1. Fleischmann R, Schechtmann J, Bennett R, Handel ML, Burmester GR, Tesser J, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHulL-1ra) in patients with rheumatoid arthritis: a large, international, multicenter, placebocontrolled trial. Arthritis Rheum 2003;48:927-34.
2. Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 2005;64:630-3.
3. Aarntzen EHJG, van Riel PLCM, Barrera P. Refractory adult onset Still's disease and hypersensitivity to non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors: are biological agents the solution? Ann Rheum Dis 2005;64:1523-4.
4. Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis SC. Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis 2007;66:842-3.
5. Kötter I, Wacker A, Koch S, Henes J, Richter C, Engel A, et al. Anakinra in patients with treatment-resistant adult-onset still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum 2007;73:189-97.
6. Lequerré T, Quartier P, Alaoui F, De Bandt M, Mejjad O. Kone-Paut I, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008;67:302-8.
7. Ruiz PJ, Masliah E, Doherty TA, Quach A, Firesetin GS. Cardiac death in a patient with adult-onset Still's disease treated with interleukin 1 receptor inhibitor anakinra. Ann Rheum Dis 2007;66:422-3.
8. Villa AT, Pulg L, Fernández-Figueras MT, Laiz AM, Vidal D, Alomar A. Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients. Br J Dermatol 2005;153:417-23.